Elevance Health Inc. (0HG8.L)
USD 427.08
(-2.57%)
USD 427.08
(-2.57%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 10.49 Billion USD | 3.59% |
| 2022 | 10.12 Billion USD | 2.35% |
| 2021 | 6 Billion USD | 24.82% |
| 2020 | 8.17 Billion USD | 3.85% |
| 2019 | 7.21 Billion USD | 14.9% |
| 2018 | - USD | 27.62% |
| 2017 | 77.21 Billion USD | -11.21% |
| 2016 | 5.57 Billion USD | -1.29% |
| 2015 | 5.61 Billion USD | 6.13% |
| 2014 | 5.29 Billion USD | 9.9% |
| 2013 | 4.79 Billion USD | 3.1% |
| 2012 | - USD | 0.24% |
| 2011 | 4.72 Billion USD | 3.1% |
| 2010 | 5.11 Billion USD | -40.65% |
| 2009 | 8.4 Billion USD | 132.67% |
| 2008 | 4.17 Billion USD | -44.77% |
| 2007 | 6.25 Billion USD | 5.88% |
| 2006 | 5.87 Billion USD | 22.0% |
| 2005 | 4.58 Billion USD | 162.66% |
| 2004 | 1.85 Billion USD | 17.64% |
| 2003 | 1.59 Billion USD | 51.78% |
| 2002 | 255.5 Million USD | 49.53% |
| 2001 | 645.1 Million USD | -96.27% |
| 2000 | 17.31 Billion USD | 40.19% |
| 1999 | 12.35 Billion USD | 11.55% |
| 1998 | 11.07 Billion USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 2 Billion USD | -44.4% |
| 2024 Q2 | 3.6 Billion USD | 1.87% |
| 2024 Q1 | 3.53 Billion USD | 109.92% |
| 2023 Q1 | 3.33 Billion USD | 79.53% |
| 2023 Q2 | 3.13 Billion USD | -5.91% |
| 2023 FY | - USD | -81.57% |
| 2023 Q3 | 2.33 Billion USD | -25.39% |
| 2023 Q4 | 1.68 Billion USD | -28.0% |
| 2022 Q2 | -205 Million USD | -107.64% |
| 2022 Q1 | 2.68 Billion USD | 74.85% |
| 2022 Q3 | 2.59 Billion USD | 1366.83% |
| 2022 Q4 | 1.4 Billion USD | -46.05% |
| 2022 FY | - USD | 2.35% |
| 2021 Q1 | 2.45 Billion USD | 249.64% |
| 2021 Q2 | 2.66 Billion USD | 8.3% |
| 2021 Q4 | 1.53 Billion USD | -34.6% |
| 2021 Q3 | 2.34 Billion USD | -11.83% |
| 2021 FY | - USD | 24.82% |
| 2020 Q4 | 703 Million USD | 0.86% |
| 2020 Q3 | 697 Million USD | -79.71% |
| 2020 FY | - USD | 3.85% |
| 2020 Q1 | 2.35 Billion USD | 99.92% |
| 2020 Q2 | 3.43 Billion USD | 45.61% |
| 2019 Q3 | 1.79 Billion USD | 2.29% |
| 2019 Q1 | 2.23 Billion USD | 168.83% |
| 2019 Q2 | 1.75 Billion USD | -21.67% |
| 2019 Q4 | 1.18 Billion USD | -34.08% |
| 2019 FY | - USD | 14.9% |
| 2018 Q4 | 831 Million USD | -45.7% |
| 2018 FY | - USD | 27.62% |
| 2018 Q3 | 1.53 Billion USD | -14.48% |
| 2018 Q2 | 1.78 Billion USD | -12.71% |
| 2018 Q1 | 2.05 Billion USD | 482.88% |
| 2017 Q2 | 1.42 Billion USD | -17.93% |
| 2017 Q3 | 1.16 Billion USD | -18.51% |
| 2017 Q4 | 351.7 Million USD | -69.7% |
| 2017 FY | - USD | -11.21% |
| 2017 Q1 | 1.73 Billion USD | 146.13% |
| 2016 Q3 | 1.36 Billion USD | -18.48% |
| 2016 Q1 | 1.53 Billion USD | 256.02% |
| 2016 FY | - USD | -1.29% |
| 2016 Q4 | 705.2 Million USD | -48.33% |
| 2016 Q2 | 1.67 Billion USD | 8.9% |
| 2015 Q4 | 431.8 Million USD | -60.76% |
| 2015 Q3 | 1.1 Billion USD | -46.31% |
| 2015 Q2 | 2.04 Billion USD | 14.92% |
| 2015 FY | - USD | 6.13% |
| 2015 Q1 | 1.78 Billion USD | 62.84% |
| 2014 FY | - USD | 9.9% |
| 2014 Q4 | 1.09 Billion USD | -15.8% |
| 2014 Q3 | 1.3 Billion USD | -11.9% |
| 2014 Q2 | 1.47 Billion USD | 9.62% |
| 2014 Q1 | 1.34 Billion USD | 93.09% |
| 2013 Q2 | 1.43 Billion USD | -4.04% |
| 2013 FY | - USD | 3.1% |
| 2013 Q4 | 697.5 Million USD | -26.53% |
| 2013 Q3 | 949.4 Million USD | -34.0% |
| 2013 Q1 | 1.49 Billion USD | 122.25% |
| 2012 Q2 | 1.23 Billion USD | -17.33% |
| 2012 Q3 | 1.08 Billion USD | -11.46% |
| 2012 Q4 | 674.5 Million USD | -38.1% |
| 2012 FY | - USD | 0.24% |
| 2012 Q1 | 1.48 Billion USD | 126.22% |
| 2011 Q4 | 658 Million USD | -45.03% |
| 2011 Q3 | 1.19 Billion USD | 3.0% |
| 2011 Q2 | 1.16 Billion USD | -26.34% |
| 2011 Q1 | 1.57 Billion USD | 23.78% |
| 2011 FY | - USD | 3.1% |
| 2010 Q2 | 1.19 Billion USD | -12.65% |
| 2010 Q3 | 1.16 Billion USD | -2.43% |
| 2010 Q4 | 1.27 Billion USD | 9.74% |
| 2010 FY | - USD | -40.65% |
| 2010 Q1 | 1.36 Billion USD | -68.8% |
| 2009 Q4 | 4.36 Billion USD | 281.96% |
| 2009 Q2 | 1.11 Billion USD | 21.68% |
| 2009 Q1 | 919.7 Million USD | 72.07% |
| 2009 FY | - USD | 132.67% |
| 2009 Q3 | 1.14 Billion USD | 2.19% |
| 2008 Q4 | 534.5 Million USD | -13.97% |
| 2008 Q2 | 1.09 Billion USD | 6.77% |
| 2008 Q3 | 621.3 Million USD | -43.17% |
| 2008 Q1 | 1.02 Billion USD | -30.2% |
| 2008 FY | - USD | -44.77% |
| 2007 Q4 | 1.46 Billion USD | -3.37% |
| 2007 Q3 | 1.51 Billion USD | 3.36% |
| 2007 Q2 | 1.46 Billion USD | 5.62% |
| 2007 Q1 | 1.39 Billion USD | -3.34% |
| 2007 FY | - USD | 5.88% |
| 2006 Q4 | 1.43 Billion USD | 2.3% |
| 2006 Q3 | 1.4 Billion USD | 3.89% |
| 2006 Q2 | 1.35 Billion USD | 2.45% |
| 2006 Q1 | 1.32 Billion USD | 10.28% |
| 2006 FY | - USD | 22.0% |
| 2005 Q2 | 1.07 Billion USD | 0.0% |
| 2005 Q3 | 1.18 Billion USD | 9.99% |
| 2005 FY | - USD | 162.66% |
| 2005 Q4 | 1.19 Billion USD | 1.5% |
| 2005 Q1 | 1.07 Billion USD | 160.75% |
| 2004 Q2 | 425.9 Million USD | -5.65% |
| 2004 Q1 | 451.4 Million USD | 15.98% |
| 2004 FY | - USD | 17.64% |
| 2004 Q4 | 411.5 Million USD | -5.1% |
| 2004 Q3 | 433.6 Million USD | 1.81% |
| 2003 Q3 | 355 Million USD | 10.16% |
| 2003 Q2 | 323.2 Million USD | -5.07% |
| 2003 FY | - USD | 51.78% |
| 2003 Q4 | 421.8 Million USD | 3.7% |
| 2003 Q1 | 262.9 Million USD | 10.3% |
| 2002 Q3 | 193.5 Million USD | 47.03% |
| 2002 FY | - USD | 49.53% |
| 2002 Q2 | 180.9 Million USD | 4.89% |
| 2002 Q1 | 46.1 Million USD | 22.34% |
| 2002 Q4 | 325.4 Million USD | 18.54% |
| 2001 FY | - USD | -96.27% |
| 2001 Q3 | 185.2 Million USD | 0.0% |
| 2001 Q4 | 145.5 Million USD | -21.44% |
| 2000 FY | - USD | 40.19% |
| 1999 FY | - USD | 11.55% |
| 1998 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Phreesia, Inc. | -102.94 Million USD | 10289.907% |
| Accuray Incorporated | 9 Million USD | -116339.116% |
| Align Technology, Inc. | 799.03 Million USD | -1212.827% |
| AxoGen, Inc. | -13.32 Million USD | 78806.483% |
| Boston Scientific Corporation | 3.61 Billion USD | -190.34% |
| CVS Health Corporation | 18.17 Billion USD | 42.293% |
| Cardinal Health, Inc. | 1.97 Billion USD | -430.334% |
| Centene Corporation | -463 Million USD | 2365.659% |
| DaVita Inc. | 2.34 Billion USD | -347.059% |
| HCA Healthcare, Inc. | 12.72 Billion USD | 17.538% |
| Hologic, Inc. | 1.29 Billion USD | -709.289% |
| Humana Inc. | -561 Million USD | 1969.875% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | -761.485% |
| Laboratory Corporation of America Holdings | 1.34 Billion USD | -677.383% |
| Masimo Corporation | 236.7 Million USD | -4331.77% |
| McKesson Corporation | 4.66 Billion USD | -124.77% |
| Patterson Companies, Inc. | 374.75 Million USD | -2699.155% |
| Quest Diagnostics Incorporated | 1.73 Billion USD | -505.658% |
| ResMed Inc. | 1.6 Billion USD | -555.49% |
| Henry Schein, Inc. | 943 Million USD | -1012.407% |
| Teladoc Health, Inc. | 153.99 Million USD | -6711.821% |
| Universal Health Services, Inc. | 1.74 Billion USD | -501.69% |
| Veeva Systems Inc. | 429.33 Million USD | -2343.319% |
| Baxter International Inc. | 2.77 Billion USD | -277.882% |
| Becton, Dickinson and Company | 4.27 Billion USD | -145.38% |
| Intuitive Surgical, Inc. | 2.39 Billion USD | -338.16% |
| Danaher Corporation | 7.49 Billion USD | -39.885% |
| Stryker Corporation | 5.16 Billion USD | -103.295% |
| Medtronic plc | 9.05 Billion USD | -15.835% |